US stock · Healthcare sector · Drug Manufacturers—General
Company Logo

Merck & Co., Inc.

MRKNYSE

86.17

USD
-0.01
(-0.02%)
Market Open
13.16P/E
12Forward P/E
0.66P/E to S&P500
218.280BMarket CAP
3.11%Div Yield
Upcoming Earnings
27 Oct
Shares Short
8/31/22
19.29M
Short % of Float
0.76%
Short % of Shares Outs.
0.76%
% Held by Insiders
0.11%
% Held by Institutions
76.27%
Beta
0.34
PEG Ratio
1.08
52w. high/low
95.72/71.50
Avg. Daily Volume
8.59M
Return %
Stock
S&P 500
1 year
18.90
(17.80)
3 years
17.75
23.21
5 years
61.20
45.98
Scale: |
High
Low
34.94
23.30
34.69
13.33
24.00
12.07
25.96
19.38
25.86
19.63
33.78
25.18
36.92
29.01
46.90
36.34
48.34
35.26
52.66
37.67
55.01
44.43
68.58
44.38
81.97
62.06
81.52
58.19
89.76
65.46
95.72
72.23
Currency: USD
2006
2007
2008
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
TTM
Revenue per share
10.39
11.15
11.17
13.01
14.86
15.80
15.62
15.04
14.88
14.20
14.48
14.88
16.31
18.45
18.97
19.25
22.61
Earnings per share
2.04
1.51
3.66
6.12
0.28
2.06
2.04
1.50
4.20
1.60
1.43
0.89
2.40
3.88
2.79
5.16
6.56
FCF per share
2.66
2.76
2.47
0.92
2.95
3.51
2.67
3.45
1.95
4.00
3.19
1.69
3.20
3.93
2.20
3.82
5.69
Dividends per share
1.53
1.52
1.54
1.65
1.57
1.58
1.73
1.80
1.85
1.84
1.86
1.92
1.99
2.24
2.46
2.61
2.69
CAPEX per share
0.45
0.47
0.61
0.69
0.54
0.57
0.65
0.53
0.82
0.46
0.59
0.70
1.01
1.37
1.85
1.76
1.78
Book Value per sh.
8.06
8.38
8.78
28.01
17.57
17.93
17.52
17.00
17.14
16.06
14.58
12.73
10.30
10.20
10.01
15.09
15.63
Comm.Shares outs.
2,178
2,171
2,136
2,109
3,095
3,041
3,027
2,928
2,838
2,781
2,749
2,697
2,593
2,539
2,530
2,530
2,529
Avg. annual P/E ratio
10.2
18.8
5.8
2.9
82.4
11.0
14.1
22.2
10.2
27.2
31.9
57.2
22.6
18.4
25.8
14.3
13.2
P/E to S&P500
0.6
1.1
0.3
0.0
4.0
0.7
0.9
1.3
0.6
1.4
1.4
2.4
0.9
0.8
0.7
0.5
0.7
Avg. annual div. yield
7.4%
5.4%
7.3%
9.2%
6.8%
7.0%
6.0%
5.4%
4.3%
4.2%
4.1%
3.8%
3.7%
3.1%
3.4%
3.5%
3.2%
Revenue (m)
22,636
24,198
23,850
27,428
45,987
48,047
47,267
44,033
42,237
39,498
39,807
40,122
42,294
46,840
47,994
48,704
57,169
Operating margin
16.3%
23.2%
25.5%
14.7%
7.3%
18.7%
20.9%
17.4%
15.8%
19.1%
15.1%
18.2%
21.1%
26.1%
17.7%
27.1%
33.8%
Depreciation (m)
2,268
1,988
1,631
2,576
7,381
7,427
6,978
6,988
6,691
6,375
5,441
4,637
4,519
3,652
3,625
3,214
2,714
Net profit (m)
4,434
3,275
7,808
12,901
861
6,272
6,168
4,404
11,920
4,442
3,920
2,394
6,220
9,843
7,067
13,049
16,579
Income tax rate
28.7%
2.8%
20.4%
14.8%
40.6%
12.8%
27.9%
18.5%
30.9%
17.4%
15.4%
62.9%
28.8%
14.7%
19.4%
11.0%
9.7%
Net profit margin
19.6%
13.5%
32.7%
47.0%
1.9%
13.1%
13.0%
10.0%
28.2%
11.2%
9.8%
6.0%
14.7%
21.0%
14.7%
26.8%
29.2%
Working capital (m)
2,508
2,787
4,986
12,678
13,423
16,936
16,509
17,817
14,407
10,561
13,410
6,152
3,669
5,263
437
6,394
8,948
Long-term debt (m)
5,551
3,916
3,943
16,075
15,482
15,525
16,254
20,539
18,699
23,929
24,274
21,353
19,806
22,736
25,360
30,690
28,684
Equity (m)
17,560
18,185
18,758
59,058
54,376
54,517
53,020
49,765
48,647
44,676
40,088
34,336
26,701
25,907
25,317
38,184
43,243
ROIC
15.1%
9.7%
25.6%
14.2%
1.5%
8.0%
7.9%
6.0%
15.6%
6.1%
5.8%
3.9%
11.2%
17.1%
12.1%
16.7%
23.6%
Return on capital
14.8%
7.3%
21.9%
14.3%
2.2%
7.8%
9.0%
6.0%
18.3%
6.0%
5.6%
8.3%
11.5%
14.7%
10.5%
14.6%
19.9%
Return on equity
25.2%
18.0%
41.6%
21.8%
1.6%
11.5%
11.6%
8.8%
24.5%
9.9%
9.8%
7.0%
23.3%
38.0%
27.9%
34.2%
38.3%
Plowback ratio
25.1%
(1.0)%
58.0%
73.0%
(463.6)%
23.3%
15.1%
(19.8)%
56.0%
(15.2)%
(30.7)%
(115.8)%
16.8%
42.1%
12.1%
49.3%
58.9%
Div.&Repurch./FCF
68.4%
64.1%
111.9%
180.1%
70.5%
63.2%
97.0%
116.7%
233.6%
83.5%
97.7%
201.4%
171.7%
105.1%
134.6%
77.1%
51.5%
Capital Structure
5 Aug · 2022 | Q2
All numbers in millions
Total liabilities
$ 52,880
Total assets
$ 96,123
Long-term debt
$ 28,684
Cash and equiv.
$ 9,675
Goodwill
$ 21,213
Retained earnings
$ 58,437
Common stock
2,531
Enterprise Value
$ 237,289
Working Capital
Currency: USD, in millions
2019
2020
2021
Cash & Investments
10,450
8,847
8,096
Receivables
6,778
7,851
9,230
Inventory
5,978
6,310
5,953
Other
4,277
3,142
5,407
Current assets
27,483
27,764
30,266
Acc. Payable
3,738
4,594
4,609
Debt due
3,610
6,431
2,412
Other
14,872
16,302
16,851
Current liabilities
22,220
27,327
23,872
Annual growth rates
(avg. rate of change)
1 year
5 years
10 years
Revenue
1.48%
5.03%
0.47%
Cash flow
73.48%
32.89%
15.92%
Earnings
84.65%
68.63%
33.68%
Dividends
6.36%
6.42%
2.71%
Book value
50.82%
5.83%
(1.98)%
Insider Trading
Type
Shares
Date
Frazier Kenneth C
Award
28,532
08/03/22
Guindo Chirfi
Award
110,705
08/03/22
Williams David Michael
Award
17,119
08/03/22
Coe Mary Ellen
Award
356
06/30/22
Glocer Thomas H
Award
494
06/30/22
Quarterly Revenue
Currency: USD, in millions
Year
1Q
2Q
3Q
4Q
Total
2020
12,057
10,872
12,551
12,515
47,995
2021
12,080
11,402
13,154
13,521
50,157
2022
15,901
14,593
- -
- -
- -
Earnings per share
Currency: USD
Year
1Q
2Q
3Q
4Q
Total
2020
1.27
1.19
1.16
(0.83)
2.79
2021
1.26
0.61
1.81
1.49
5.16
2022
1.70
1.56
- -
- -
- -
Quarterly dividends paid
Currency: USD
Year
1Q
2Q
3Q
4Q
Total
2020
0.61
0.62
0.61
0.61
2.46
2021
0.65
0.66
0.65
0.65
2.61
2022
0.69
0.70
- -
- -
- -
Company Description
Sector:
Healthcare
Industry:
Drug Manufacturers—General
CEO:
Mr. Kenneth Frazier
Full-time employees:
67,000
City:
Kenilworth
Address:
2000 Galloping Hill Rd
IPO:
Jun 15, 1946
Website:
Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes, as well as vaccine products, such as preventive pediatric, adolescent, and adult vaccines. The Animal Health segment discovers, develops, manufactures, and markets veterinary pharmaceuticals, vaccines, and health management solutions and services, as well as digitally connected identification, traceability, and monitoring products. It serves drug wholesalers and retailers, hospitals, and government agencies; managed health care providers, such as health maintenance organizations, pharmacy benefit managers, and other institutions; and physicians and physician distributors, veterinarians, and animal producers. The company has collaborations with AstraZeneca PLC; Bayer AG; Eisai Co., Ltd.; Ridgeback Biotherapeutics; and Gilead Sciences, Inc. to jointly develop and commercialize long-acting treatments in HIV. Merck & Co., Inc. was founded in 1891 and is headquartered in Kenilworth, New Jersey.
Recent News
· 26 Jul, 2022 · The Wall Street Journal
· 15 Jul, 2022 · The Wall Street Journal
· 7 Jul, 2022 · The Wall Street Journal
· 23 Jun, 2022 · The Wall Street Journal
· 22 Jun, 2022 · The Wall Street Journal
· 18 Jun, 2022 · The Wall Street Journal
· 24 May, 2022 · The Wall Street Journal
· 14 Mar, 2022 · The Wall Street Journal
· 28 Jan, 2022 · The Wall Street Journal
· 23 Dec, 2021 · The Wall Street Journal
· 26 Nov, 2021 · The Wall Street Journal
· 11 Oct, 2021 · The Wall Street Journal
· 1 Oct, 2021 · The Wall Street Journal